Journal
SURVEY OF OPHTHALMOLOGY
Volume 47, Issue -, Pages S105-S115Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0039-6257(02)00327-2
Keywords
bimatoprost; glaucoma; intraocular pressure; ocular hypertension; latanoprost; timolol; travoprost
Categories
Ask authors/readers for more resources
Bimatoprost (Lumigan(TM) [Allergan, Inc, Irvine GA]) and travoprost (Travatan(TM) [Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for use in patients with glaucoma and ocular hypertension. This review evaluates recent studies comparing these new drugs with timolol and with latanoprost. In each study, the statistical analyses support the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP. The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available